NCT06415994
Multimodal Fetal and Placental Imaging and Biomarkers of Clinical Outcomes in Opioid Use Disorder
Enrolling by Invitation
Not specifiedAges 18+ObservationalSenthil SadhasivamInvestigator-initiated
~250 participants
Updated 2026-07-14 on ClinicalTrials.gov
What's tested:Buprenorphine or Methadone TreatmentFetal and Placental MRIChild Developmental AssessmentQuestionnairesBlood and Placental Samples
At a glance
Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Alterations in fetal brain volume
Measured over Between 20 weeks gestation and delivery
+1 more outcome measured
Conditions
Where it's being run
2 sites across 2 statesIndiana1
Pennsylvania1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Age \>18 years
Currently taking buprenorphine or methadone for OUD and are enrolled in a prenatal opioid maintenance program
Singleton Pregnancy
Planned delivery at Indiana University or University of Pittsburgh study sites
Exclusion
Serious maternal medical illness as deemed by study physician investigators that would make it challenging to comply with study procedures
Known or suspected major fetal/ neonatal congenital abnormalities
HIV or AIDS
What this trial measures
- Alterations in fetal brain volumeBetween 20 weeks gestation and delivery
Comparing changes in fetal brain volume using MRI between babies who have had prenatal opioid exposure (POE) and controls
- Differences in placenta signalBetween 20 weeks gestation and delivery
Comparing differences in placenta signal using MRI between the POE group and controls